Oculis Reports the Completion of Patient Enrolment in P-III Trial (OPTIMIZE) of OCS-01 for the Treatment of Inflammation and Pain
- The company has completed the patient enrolment in the P-III trial (OPTIMIZE) evaluating the efficacy and safety of OCS-01 vs vehicle in 240 patients with inflammation and pain following cataract surgery at 25 participating sites across the US
- In the P-II study (SKYGGN), OCS-01 met it's 1EPs & 2EPs in the absence of anterior chamber cells and absence of pain, achieved statistical significance for patients with OCS-01 was more effective than a vehicle, was well tolerated & the results were presented at ASCRS 2020 annual meeting and published in Clinical Therapeutics
- OCS-01 is also being studied in an ongoing P-III study (DIAMOND) for DME and additional results are expected in 2023
Ref: GlobeNewswire | Image: Oculis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.